Combined Docetaxel/Pictilisib-Loaded mPEGylated Nanocarriers with Dual HER2 Targeting Antibodies for Synergistic Chemotherapy of Breast Cancer

Combined Docetaxel/Pictilisib-Loaded mPEGylated Nanocarriers with Dual HER2 Targeting Antibodies for Synergistic Chemotherapy of Breast Cancer

Wei-Jie Cheng,1,&ast; Shyr-Yi Lin,2,3,&ast; Kuo-Hsiang Chuang,4,5,&ast; Michael Chen,4 Hsiu-O Ho,1 Ling-Chun Chen,6 Chien-Ming Hsieh,1 Ming-Thau Sheu1 1School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan; 2Division of Gastroenterology, Department of Interna...

Full description

Bibliographic Details
Main Authors:	Cheng WJ, Lin SY, Chuang KH, Chen M, Ho HO, Chen LC, Hsieh CM, Sheu MT
Format:	Article
Language:	English
Published:	Dove Medical Press 2022-11-01
Series:	International Journal of Nanomedicine
Subjects:	docetaxel pictilisib nanocarriers bispecific antibodies dual epitopes her2-positive breast cancer
Online Access:	https://www.dovepress.com/combined-docetaxelpictilisib-loaded-mpegylated-nanocarriers-with-dual--peer-reviewed-fulltext-article-IJN

Similar Items

Pictilisib-Induced Resistance Is Mediated through FOXO1-Dependent Activation of Receptor Tyrosine Kinases in Mucinous Colorectal Adenocarcinoma Cells
by: Murali R. Kuracha, et al.
Published: (2023-08-01)

Inhibition of Phosphatidylinositol 3-Kinase by Pictilisib Blocks Influenza Virus Propagation in Cells and in Lungs of Infected Mice
by: Stefanie Deinhardt-Emmer, et al.
Published: (2021-05-01)

Silencing Glypican-1 enhances the antitumor effects of Pictilisib via downregulating PI3K/Akt/ERK signaling in chemo-resistant esophageal adenocarcinoma
by: Akshay Pratap, et al.
Published: (2023-12-01)

Pyrotinib alone or in combination with docetaxel in refractory HER2‐positive gastric cancer: A dose‐escalation phase I study
by: Dan Liu, et al.
Published: (2023-05-01)

Glucose-Modified Zein Nanoparticles Enhance Oral Delivery of Docetaxel
by: Yabing Xing, et al.
Published: (2022-06-01)

A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer
by: Dongdong Xu, et al.
Published: (2024-02-01)

Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis
by: Wu Lin, et al.
Published: (2023-10-01)

Docetaxel-induced radiation recall dermatitis
by: EG Kandemir, et al.
Published: (2005-01-01)

Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
by: Shuying Liu, et al.
Published: (2023-06-01)

Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension (NDLS) versus Conventional Docetaxel as Neoadjuvant and Adjuvant Therapy for Primary Operable Breast Cancer
by: Badiginchala R, et al.
Published: (2023-04-01)

Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview
by: S. Aishah A. Razak, et al.
Published: (2021-01-01)

Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer
by: Atsuto Mouri, et al.
Published: (2019-04-01)

Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody
by: Jackie Cheng, et al.
Published: (2020-09-01)

Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma
by: Nami Tateyama, et al.
Published: (2022-11-01)

Functionalized Lipid Nanocarriers for Simultaneous Delivery of Docetaxel and Tariquidar to Chemoresistant Cancer Cells
by: Chang Hyun Kim, et al.
Published: (2023-02-01)

Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer
by: Kosuke Hamai, et al.
Published: (2023-04-01)

HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
by: Jeongmin Seo, et al.
Published: (2023-12-01)

The effect of docetaxel on retinal pigment epithelial cells
by: Jialin Li, et al.
Published: (2022-01-01)

Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor
by: Weiliang Zhuang, et al.
Published: (2023-11-01)

Development and characterization of docetaxel and curcumin-loaded aerosolized nanoemulsion for pulmonary cancer
by: Asmawi, Azren Aida
Published: (2020)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
by: Hui-Li Wong, et al.
Published: (2015-06-01)

Nanocrystal-Loaded Micelles for the Enhanced In Vivo Circulation of Docetaxel
by: Meng Cheng, et al.
Published: (2021-07-01)

A Tetravalent Biparatopic Antibody Causes Strong HER2 Internalization and Inhibits Cellular Proliferation
by: Filippo Benedetti, et al.
Published: (2021-10-01)

A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer
by: Daniel A. Vallera, et al.
Published: (2021-08-01)

Identification of Potential Serum Protein Biomarkers in Thymoma with Myasthenia Gravis After Docetaxel Treatment
by: Hongxia Yang, et al.
Published: (2023-02-01)

Histopathological Efficacy of Docetaxel Versus Paclitaxel As First Line Chemotherapy for Epithelial Ovarian Carcinoma
by: Tayyup Şimşek, et al.
Published: (2008-12-01)

Population pharmacokinetics of docetaxel in patients with solid tumors
by: XI Xin, et al.
Published: (2022-11-01)

The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial
by: Deyue Liu, et al.
Published: (2022-06-01)

Inclusion Complex of Docetaxel with Sulfobutyl Ether β-Cyclodextrin: Preparation, In Vitro Cytotoxicity and In Vivo Safety
by: Lili Ren, et al.
Published: (2020-10-01)

Grover disease associated with docetaxel chemotherapy
by: Shawn Afvari, BS, et al.
Published: (2022-11-01)

Co-Adjuvant Therapy Efficacy of Catechin and Procyanidin B2 with Docetaxel on Hormone-Related Cancers In Vitro
by: Mª Jesús Núñez-Iglesias, et al.
Published: (2021-07-01)

HER2/neu-Based Peptide Vaccination-Pulsed with B-Cell Epitope Induced Efficient Prophylactic and Therapeutic Antitumor Activities in TUBO Breast Cancer Mice Model
by: Muhammad Luqman Nordin, et al.
Published: (2021-10-01)

Fabrication of curcumin-loaded magnetic PEGylated-PLGA nanocarriers tagged with GRGDS peptide for improving anticancer activity
by: Fatih Senturk, et al.
Published: (2023-01-01)

Design and Synthesis of Amphiphilic Graft Polyphosphazene Micelles for Docetaxel Delivery
by: Diana Serbezeanu, et al.
Published: (2023-05-01)

Development of docetaxel nanocrystals surface modified with transferrin for tumor targeting
by: Choi JS, et al.
Published: (2016-12-01)

Induction chemotherapy regimen of docetaxel plus cisplatin versus docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of an open-label, noninferiority, multicentre, randomised, controlled phase 3 trial
by: Yan Wang, et al.
Published: (2022-11-01)

New Ways to Treat Tuberculosis Using Dendrimers as Nanocarriers
by: Serge Mignani, et al.
Published: (2018-07-01)

Bufalin reverses ABCB1-mediated resistance to docetaxel in breast cancer
by: Die Zhang, et al.
Published: (2023-03-01)

The Fabrication of Docetaxel-Containing Emulsion for Drug Release Kinetics and Lipid Peroxidation
by: Yifang Wu, et al.
Published: (2022-09-01)

Enhanced anti-breast cancer efficacy of co-delivery liposomes of docetaxel and curcumin
by: Xi Ye, et al.
Published: (2022-10-01)